Study of Ociperlimab (BGB-A1217) in Combination With Tislelizumab in Advanced Solid Tumors
Completed · Phase 1
Conditions studied: Locally Advanced and Metastatic Solid Tumors
In brief
The primary objectives of this study were: to assess the safety and tolerability, to determine the maximum tolerated dose (MTD) or maximum administered dose (MAD) and to determine the recommended Phase 2 dose (RP2D) of BGB-A1217 (known as ociperlimab) in combination with tislelizumab in participants with advanced solid tumors in phase 1. Primary objective of Phase 1b was to assess overall response rate (ORR) determined by Investigator per Response Evaluation Criteria in Solid Tumors (RECIST) version (v).1.1 for patients in each dose-expansion cohort.
Key facts
- Study ID
- NCT04047862
- Run by
- BeiGene
- People needed
- 446
- Starts
- 2019-08-15
- Expected to finish
- 2024-08-07
- Last updated by the study team
- 2025-08-22
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Scri Florida Cancer Specialists South — Fort Myers, Florida, United States
- Mayo Clinic Jacksonville — Jacksonville, Florida, United States
- Scri Florida Cancer Specialists North — St. Petersburg, Florida, United States
- University of Kansas Medical Center Research Institute — Kansas City, Kansas, United States
- University of Minnesota — Minneapolis, Minnesota, United States
- Mayo Clinic Rochester — Rochester, Minnesota, United States
- Rutgers Cancer Institute of New Jersey — New Brunswick, New Jersey, United States
- Providence Portland Medical Center — Portland, Oregon, United States
- Tennessee Oncology, Pllc Nashville — Nashville, Tennessee, United States
- Medical College of Wisconsin — Milwaukee, Wisconsin, United States
- Blacktown Cancer and Haematology Centre — Blacktown, New South Wales, Australia
- Chris Obrien Lifehouse — Camperdown, New South Wales, Australia
- Pindara Private Hospital — Benowa, Queensland, Australia
- Icon Cancer Foundation — South Brisbane, Queensland, Australia
- Metro South Health, Cancer Trials Unit Division of Cancer Services Pah — Woolloongabba, Queensland, Australia
- Ashford Cancer Centre Research Northeast — Windsor Gardens, South Australia, Australia
- Royal Hobart Hospital — Hobart, Tasmania, Australia
- Bendigo Health — Bendigo, Victoria, Australia
- Monash Health — Clayton, Victoria, Australia
- St Vincents Hospital — Fitzroy, Victoria, Australia
- Linear Clinical Research — Nedlands, Western Australia, Australia
- St John of God Health Care — Subiaco, Western Australia, Australia
- The Second Hospital of Anhui Medical University — Hefei, Anhui, China
- Beijing Tongren Hospital, Cmu — Beijing, Beijing Municipality, China
- Mayo Clinic Phoenix — Phoenix, Arizona, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.